Illuminating biomarker detection – Leading the way in personalized medicine.

ApoCell Awarded Phase I SBIR Grant
September 30, 2011 – ApoCell, Inc. (Houston, TX) awarded a nine month, Phase I SBIR grant towards the development of a Point of Care Device for Antibody Independent Isolation of Circulating Tumor Cells.

ApoCell Awarded $2.9 Million from SAIC-Frederick Inc.
Press Release, August 10, 2011 – ApoCell, Inc. (Houston, TX) awarded $2.9 million from SAIC-Frederick Inc. to deliver a new platform for detection and molecular analysis of Circulating Tumor Cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program.

ApoCell Launches Revolutionary Circulating Cancer Cell Detection System
Enhanced Online News, June 1, 2011 – ApoCell, Inc. (Houston, TX) announced today that it has completed the first prototype to commercialize a revolutionary technology that improves the detection of more types of cancer cells circulating in the blood, including rare cell types that have previously gone undetected.

Climbing the Informatics Mountain—It’s Not a Bubble: Highlights From the 2011 Tri-Conference
American Laboratory, April 08, 2011 – ApoCell (Houston, TX) introduced an instrument that quickly separates CTCs and other rare cells from whole blood. The instrument uses dielectrophoresis coupled with field flow fractionation (DEP-FFF) for the cell separation.

Summit Partners Invests in ApoCell
September 30, 2009, HOUSTON, TX and BOSTON, MA— ApoCell, Inc. announced that it has received an investment from growth equity investor Summit Partners. The investment will be used to fund ApoCell’s organic growth initiatives and continued development of the company’s state-of-the-art technology platforms.